Castle Biosciences, Inc. develops and commercializes molecular diagnostic tests used to guide care in dermatologic and gastroenterological disease. Its recurring updates focus on test report volume, revenue performance, guidance, and clinical evidence for products such as DecisionDx-Melanoma and TissueCypher.
Company news also covers studies, publications, and medical-meeting presentations involving risk stratification for cutaneous melanoma, sentinel lymph node biopsy decision support through DecisionDx-Melanoma’s i31-SLNB result, and Barrett’s esophagus progression-risk assessment with TissueCypher. Financial releases frequently discuss core revenue drivers, reimbursement effects, commercial focus, and quarterly operating results.
Castle Biosciences (CSTL) will release its third-quarter financial results after market close on Nov. 5, 2026, and host a webcast. The results will cover the quarter and nine months ended Sept. 30, 2026. Management will discuss the results at 4:30 p.m. Eastern time, followed by a brief question-and-answer session. A webcast replay will be available afterward.
Castle Biosciences (CSTL) announced three TissueCypher studies evaluating molecular risk assessment in Barrett's esophagus for presentation at ACG 2026.
The research includes two case reports and a multi-center study. In the cohort, management recommendations changed consistently with TissueCypher risk classifications for 96% of patients. TissueCypher classified 83% as low risk and 17% as intermediate/high risk, versus 31% and 69%, respectively, with the Progression in Barrett's clinical and pathology-based approach. Agreement between the approaches was slight. Physicians recommended five-year surveillance for 38 patients and endoscopic treatment for eight. Both case reports described high-risk test results followed by detection of previously undetected high-grade dysplasia, an advanced precancerous change.
Castle Biosciences (CSTL) will present DecisionDx-Melanoma study findings on biopsy decisions and recurrence risk at the EADV Congress 2026. A prospective study enrolled 2,799 patients across 29 U.S. centers. Among 676 patients who underwent sentinel lymph node biopsy (SLNB) and received an i31-SLNB result, observed node positivity was 4.4% in the low-risk group and 22.8% in the high-risk group. Among 565 eligible low-risk patients who skipped SLNB, five-year recurrence-free survival (RFS) was 99.6%.
Early-stage patients with high-risk Class 2B results had RFS similar to stage IIB patients. A separate analysis of 687 patients with transected melanomas—biopsies cut through the tumor base—reported five-year RFS of 93.2% for Class 1A versus 64.1% for Class 2B (p<0.001). Early-stage Class 2B patients had 73.7% RFS. Castle said the findings support test-guided biopsy decisions and follow-up care.
Castle Biosciences (CSTL) reported a published study in which TissueCypher results changed management recommendations for 90% of patients.
The study evaluated 30 patients with non-dysplastic Barrett's esophagus who received testing during care at Keck Medical Center of USC. TissueCypher classified 17% as intermediate or high risk of progression to high-grade dysplasia or esophageal adenocarcinoma within five years, and 83% as low risk. Clinicians escalated recommendations for every intermediate- or high-risk patient, including endoscopic eradication therapy for four patients and shorter-interval surveillance for one. They de-escalated recommendations for 84% of low-risk patients. Results changed recommendations or increased physicians' confidence for 97% of patients.
Castle Biosciences (CSTL) highlighted a September 8 study of atopic dermatitis treatment experiences and interest in molecular testing.
In an assessment of 43 patients and caregivers, 55% of participants who had used targeted systemic therapies modified treatment due to lack of efficacy. Interest in molecular testing to guide treatment selection was 83% overall and 94% among respondents open to starting a new systemic therapy.
AdvanceAD-Tx is designed to guide systemic treatment for patients aged 12 or older with moderate-to-severe atopic dermatitis. An earlier prospective clinical validation study found that patients with a JAK Inhibitor Responder Profile given a JAK inhibitor were 5.5 times more likely to reach at least 90% improvement in the Eczema Area and Severity Index by three months, and achieved that response 3.8 times faster, than patients with the same profile given Th2-targeted therapy. Patients with a Th2 Molecular Profile had comparable outcomes with either therapy class.
Castle Biosciences (CSTL) is opening a new 55,000-square-foot laboratory and office facility in Scottsdale, Arizona, expanding its operational footprint in the Phoenix metropolitan area.
The facility, at 8667 E. Hartford Drive in the Perimeter Center business park, is designed to support growing laboratory test volumes with upgraded HVAC, IT and security systems and backup power infrastructure. A grand opening celebration is scheduled for Oct. 6, 2026, at 3:30 p.m. MST, with government officials and community leaders expected to attend. As of June 30, 2026, the company employs more than 1,000 people across the U.S., including about 220 in the greater Phoenix area.
Castle Biosciences (CSTL) reported a published decision modeling study suggesting its TissueCypher Barrett's Esophagus test could improve risk‑aligned management for Barrett's esophagus patients.
The model used pooled data from 699 patients across five clinical validation studies with known progression outcomes. Simulated use of TissueCypher increased the share of Barrett's esophagus patients (NDBE, IND, LGD) receiving appropriate management from 59.8% to 75.3% (P<0.001). Among all progressors to high‑grade dysplasia or esophageal adenocarcinoma, appropriate escalation to short‑interval surveillance or endoscopic eradication therapy rose from 50.5% to 66.3% (31.9% reduction in undertreatment; P=0.008). Across non‑progressors, modeled overtreatment fell by 41.7% (P<0.001).
In non‑dysplastic Barrett's esophagus progressors, appropriate escalation nearly doubled from 30.4% to 56.9% (P=0.001), with improved management also seen in NDBE and IND/LGD non‑progressors.
Castle Biosciences (CSTL) reported JAAD publication of a multi-center validation study of its integrated DecisionDx-SCC (i40-GEP) test for high-risk cutaneous squamous cell carcinoma. The test combines a 40-gene expression profile with five clinicopathologic risk factors to refine prognosis and anticipated benefit from adjuvant radiation therapy (ART).
In an independent cohort of 572 patients, DecisionDx-SCC significantly stratified metastatic and local recurrence risk (p<0.0001). Class 1A (low risk) comprised 44.6% of patients and showed a 97.3% negative predictive value. Class 2B (12.9% of patients) had a three-year metastasis-free survival of 66.2% versus 97.3% for Class 1A and was 10.7 times more likely to metastasize. Class 2B patients treated with ART had about 50% lower median metastatic progression at five years than untreated Class 2B patients. The test demonstrated greater accuracy than NCCN risk groups and BWH staging.
SciBase Holding (SCIB) and Castle Biosciences (CSTL) expanded their collaboration as SciBase received an additional order worth about $0.6 million (≈MSEK 5) for its Nevisense Go pen devices and electrodes to support Castle's atopic dermatitis research.
The order will accelerate the ongoing clinical study aimed at predicting relapses in atopic dermatitis and fund preparations for a second clinical study under the existing collaboration and license agreement signed in 2025. Deliveries of the ordered devices and electrodes are expected to begin in Q4 2026. SciBase characterizes this order as a signal of collaboration expansion, supported by rapid patient recruitment in the first joint study.
Castle Biosciences (Nasdaq: CSTL) will present a company overview at Baird's 2026 Global Healthcare Conference on Tuesday, Sept. 15, 2026, at 10:50 a.m. Eastern time, with a live audio webcast and replay available on its investor relations website. The company will also participate in one-on-one investor meetings at the 10th annual Lake Street Best Ideas Growth (BIG10) Conference on Thursday, Sept. 10, 2026, with meetings requested exclusively through Lake Street Capital Markets.